Overview

Trial of BMS-986012 in Combination With Platinum and Etoposide

Status:
Active, not recruiting
Trial end date:
2021-07-26
Target enrollment:
Participant gender:
Summary
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Carboplatin
Cisplatin
Etoposide
Etoposide phosphate